If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLBB.L Regulatory News (LBB)

  • There is currently no data for LBB

Interim Results

30 Sep 2008 07:00

RNS Number : 6061E
Molectra Group Ltd
30 September 2008
Β 

ο»Ώ

For Immediate Release

30Β September 2008

Molectra Group LimitedΒ (the "Company")

Unaudited interim results for the 6 months ended 30 June 2008

Molectra Group LimitedΒ (AIM:MOLE),Β (formerly the Greenhouse Fund Limited), today reports its unaudited interim results for the 6 months ended 30 June 2008.Β 

Highlights for the period:

Additional investment in MolectraΒ Australia

Two re-bonded crumb rubber contracts awarded

Highlights post period end:

Acquired remaining minority interests in MolectraΒ Australia

Change in strategy from fund to operating company

Name change to Molectra Group Limited

New board appointments

Paul Gazzard, Chief Executive Officer commented: "The year to date has seen a transformation in both Molectra's operations and the Company's structure. The award of our first two contracts for re-bonded crumb rubber mark the change in Molectra's technology fromΒ the research and development phase toΒ a commercially viable process.

The structural changes made to Molectra have created a well funded company with a highly experienced management team and an exciting technology. With several negotiations ongoing which may lead to further contracts, we view Molectra's future with confidence."

For further information please contact:

Molectra Group Ltd

Β 

Paul GazzardΒ 

01725 510 383Β 

Rodger Sargent

020 7355 7660

Matrix Corporate Capital LLP

Stephen Mischler

020 3206 7203

Tim Graham

0203 206 7206

Threadneedle Communications Ltd

Graham Herring

020 7653 9850

CHAIRMAN'S STATEMENT

These unaudited interim accounts cover the six months to 30 June 2008.Β 

Financial performance

As at 30 June 2008, the Company had net assets of Β£12,833,702Β (2007: Β£13,574,110). The loss for the period was Β£1,465,372Β (2007: Β£238,052) and the period end NAV wasΒ 8.27p (2007:8.74p). The increased loss was due toΒ significantly increased corporate activity comparedΒ to the previous period,Β which resulted in large due diligence, legal and accounting costs.Β Β 

Portfolio update

Molectra Australia Pty Ltd ('MA')Β 

Development continued at MolectraΒ AustraliaΒ throughout the period.Β On 10 March 2008,Β MAΒ entered into its firstΒ value added product ('VAP')Β contract,Β to supply anti-cast products made from its recycled re-bonded crumb rubber to the equine market. Anti-cast products are used to create a soft and impact resistant surface on stable walls to prevent injury to horses. The contract will beΒ supplied out of theΒ BrisbaneΒ plant,Β to an individual trading as HorseFabulous ProductsΒ &Β Equipment, for distribution acrossΒ Australasia.

OnΒ 10 June 2008, a second contract,Β to supplyΒ rubberΒ automotive accessory productsΒ to an Australian distributor, was won. It is very encouraging that, despiteΒ BrisbaneΒ being a pilot plant, MAΒ is able to enter commercial agreements and this bodes well for the future, once production volumes and efficiencies are improved.Β Β 

On 15 April 2008,Β it wasΒ announcedΒ thatΒ the AUD$1,700,000Β outstanding loan from MolectraΒ to MAΒ would be repaid by the issue of further shares in Molectra, takingΒ the Company'sΒ stakeΒ in MAΒ to 64.3 per cent.Β 

There were significant post period end developments that are covered below.Β 

Other investmentsΒ 

The five Bauxsol technology sub-licences are non-core to the Company's future strategy. A strategic review to maximise shareholder value from the licenses is currently under way, the outcome of which will be announced in due course.Β 

Post period developmentsΒ 

On 16 July 2008, it was announcedΒ thatΒ the CompanyΒ had agreed, subjectΒ to the approval of shareholders at anΒ EGM,Β to acquire the 35.7% of MA's share capital thatΒ it didΒ not already own.Β The consideration for the acquisitionΒ wouldΒ be satisfied by the issue of 32,000,000Β new Molectra ordinary shares.Β In addition,Β it was announced that the CompanyΒ would acquire the intellectual propertyΒ which MAΒ relies upon for its business,Β for aΒ considerationΒ of 16,000,000Β new ordinary shares.Β 

It was also proposed thatΒ Paul Gazzard and Rodger Sargent, directors of theΒ GreenhouseΒ Strategic Adviser,Β join the Board of the Company, along withΒ John Dobozy, the inventor of theΒ MolectraΒ technology,Β and David Hassum.Β Β 

Given that the nature ofΒ the Company's business wouldΒ be transformed by these proposals, it was alsoΒ proposedΒ thatΒ the Company's name be changedΒ to MolectraΒ Group Limited. It was further proposed that the Company wouldΒ cease being an externally managed investment company and wouldΒ become an internally managed company whose principal business wouldΒ be conducted through its wholly owned subsidiary, MA.Β 

These proposals represented a fundamental change in the business, board and voting control of the Company,Β and constituted a reverse takeover under the AIM Rules,Β requiringΒ the approval of shareholders at an EGM. All resolutions were passed by shareholders at the EGM, held on 12 August 2008.

The acquisition and change in strategy allows the Company to concentrate principally on the continued commercialisation of the MAΒ tyre recycling process. Short term prospects involve securing additional contracts for the production and supply of the higher margin re-bonded crumb rubber productsΒ and, to date,Β twoΒ suchΒ contracts have been awarded, whilstΒ discussionsΒ are continuingΒ with a number of parties both in Australia and overseasΒ which may lead to additionalΒ contractsΒ beingΒ secured.Β 

Further investment will be madeΒ to enhance the production facility and increase capacity to accommodate the increasing production demandΒ for VAP's. However, a key strategy for growth is the opportunityΒ to establish tyre recycling plantsΒ for third parties, which is aΒ potentiallyΒ significantΒ area of expansion. Target industries for such plants include the mining and waste management industries, where there are restrictions and regulations on the disposal of waste tyres. Over the medium to long term the Company willΒ alsoΒ continue to improve the MolectraVacΒ microwaveΒ technology and seek to produce a carbon based product stream that is commercially viable.

The change of strategy from the portfolio approach of The Greenhouse Fund Limited to sole development of Molectra presents an exciting opportunity which I hope will allow to us to fully commercialise and enjoy the tremendous potential of Molectra's product range. I look forward to the future with great optimism.

Roger Maddock

Non-executive Director

Molectra Group Limited

30Β SeptemberΒ 2008

Β Β 

MOLECTRA GROUP LIMITED

Consolidated Condensed Interim Income Statement (Unaudited)Β 

For the six months ended 30 June 2008

(unaudited)

(unaudited)

01 January 2008

01 January 2007

to 30 June 2008

to 30 June 2007

Β£

Revenue

BankΒ interest

20,010Β 

6,088Β 

Deposit interest

122,193

184,477Β 

Other income

15,102

-

Total Income

157,305

190,565Β 

Operating expenses

Management fees

Β 

(97,732)

(97,195)

Other operating expenses

(1,212,478)

(198,246)

Amortisation of intangible asset

(231,438)

(133,176)

Depreciation of plant, property, and equipment

(35,247)

-

Total operating expenses

(1,576,896)

(428,617)

Taxation

(45,782)

-

Net loss for the period

(1,465,372)

(238,052)

Attributable to:

Equity holders of the company

(1,364,397)

(238,052)

Minority interest

(100,975)

-

Net loss for the period

(1,465,372)

(238,052)

Basic and diluted loss per share (pence)

(0.88)

(0.15)

AllΒ transactions arise from continuing operations.

Β Β 

MOLECTRA GROUPΒ LIMITED

Consolidated Condensed Interim Balance Sheet (Unaudited)

As at 30 June 2008

(unaudited)

(unaudited)

30 June 2008

30 June 2007

Β£

Β£

Non-Current Assets

Intangible assets

8,959,928

4,938,365Β 

Investments held at fair value

-

1,988,847Β 

Property, plant and equipment

723,664

-

9,683,592

6,927,212Β 

Current assets

Other receivables

57,636

24,204Β 

Cash and cash equivalents

Β 

4,505,523

6,672,737Β 

4,563,159

6,696,941Β 

Β 

Total assets

14,246,751

13,624,153Β 

Current liabilities

Other payables

(198,288)

(50,043)

Non-current liabilities

Deferred income tax liabilities

(1,214,761)

-

Net assets

12,833,702

13,574,110Β 

Equity

Share capital

14,116,977

14,116,977Β 

Other reserve

1,509

-

Retained earnings

(2,144,052)

(542,867)

11,974,434

13,574,110

Minority interest

859,268

-

Total Equity

12,833,702

13,574,110Β 

NAV per Ordinary share (pence)

8.27

8.74

Β 

These financial statements were approved by theΒ Board of Directors and signed onΒ 30thΒ September 2008.

Β Β 

MOLECTRA GROUP LIMITED

Condensed Interim Statement of Cash Flows (Unaudited)

For the six months ended 30 June 2008

(unaudited)

(unaudited)

01 January 2008

01 January 2007

to 30 June 2008

to 30 June 2007

Β£

Β£

Cash flow from operating activities

Net loss for period

(1,465,372)

(238,052)

Amortisation

266,685

133,176Β 

IncreaseΒ in deferred tax liability

45,782

-Β 

DecreaseΒ in other receivables

149,299

13,977Β 

DecreaseΒ in other payables

(352,328)

(6,752)

Net cash outflow from operating activitiesΒ 

(1,355,934)

(97,651)

Cash flow from investing activities

Purchase of property, plant, and equipment

(170,513)

-

Purchase of unlisted investments

-

(1,269,973)

Purchase of intangible investments

-

Β 

(128,740)

Net cash outflow from investing activities

(170,513)

(1,398,713)

Cash flow from financing activities

Issue of Ordinary sharesΒ 

-

-Β Β 

Sales commission and formation costs paid

-

-

Net cash inflow from financing activities

-

-Β 

Β 

Net decrease in cash and cash equivalents

(1,526,447)

(1,496,364)Β 

Cash and cash equivalents at start of the period

6,031,970

8,169,101

Cash andΒ cash equivalents at 30 June

4,505,523

6,672,737Β 

MOLECTRA GROUP LIMITED

Notes to the Condensed Interim Financial Statements (Unaudited)

1 Basis of accounting

The Group financial statements are prepared under International Financial Reporting Standards (IFRS)Β as adopted by the EU. This statement has been prepared using accounting policies & presentation consistentΒ with those applied in the preparation of the accounts for the Group for the year ended 31stΒ December 2007Β and areΒ not the company's statutory accounts for the purposes of section 240 of the Companies Act 1985.

2

Β Earnings per share

The earnings per Ordinary share is based on the netΒ loss for the period of Β£1,465,372Β (30 June 2007:Β£238,052);

and on 155,225,000 (30 June 2007:155,225,000) weighted average Ordinary shares.

The diluted return per Ordinary share is based on the net loss for the period and 155,225,000 shares. There are no potentiallyΒ 

dilutive Ordinary shares.

3

Β Management fee

01 January 2008

01 January 2007

Β 

to 30 June 2008

to 30 June 2007

Β£

Β£

Management fee

97,732

97,195

The management fee paid to Development Capital Management (Jersey) Limited is 2% per annum of the amountΒ 

subscribed plus any gains retained by the Fund for reinvestment.

The management agreement between the Fund and the Manager is terminable by either party on twelve month's

notice, subject to an initial term of 36 months from admission.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR SEIFIUSASELU
Date   Source Headline
23rd Dec 20097:30 amRNSDisposal and Potential Reverse Takeover
23rd Dec 20097:30 amRNSSuspension - Molectra Group Limited
15th Dec 20094:20 pmRNSHolding(s) in Company
29th Sep 200911:22 amRNSHolding(s) in Company
29th Sep 20097:00 amRNSInterim Results - six months ended 30 June 2009
23rd Sep 20094:44 pmRNSHolding(s) in Company
16th Jul 20094:26 pmRNSResult of AGM and Directorate Change
30th Jun 20097:00 amRNSFinal Results
20th May 20097:00 amRNSContract Update
24th Mar 20097:00 amRNSGrant of Options
20th Mar 200912:39 pmRNSHolding(s) in Company
19th Mar 20093:59 pmRNSShare buyback and total voting rights
6th Mar 20098:00 amRNSChange of Adviser
27th Feb 20093:48 pmRNSPurchase of own securities
24th Feb 20094:05 pmRNSHolding(s) in Company
11th Feb 200910:27 amRNSHolding(s) in Company
5th Feb 20094:28 pmRNSHolding(s) in Company
20th Jan 20097:00 amRNSDirectorate Change
19th Jan 20092:07 pmRNSDirector/PDMR Shareholding
7th Nov 20087:00 amRNSChange of Registered Office
28th Oct 20081:48 pmRNSHolding(s) in Company
30th Sep 20087:00 amRNSInterim Results
29th Aug 200811:44 amRNSTotal Voting Rights
18th Aug 200810:36 amRNSHolding(s) in Company
14th Aug 200811:49 amRNSConfirmation of Name Change
13th Aug 20087:00 amRNSFirst Day of Dealings
12th Aug 20084:39 pmRNSResult of AGM
12th Aug 20084:37 pmRNSResult of EGM
6th Aug 20085:53 pmRNSSchedule 1 - The Greenhouse F
16th Jul 200811:02 amRNSAcquisition of Molectra Austr
27th Jun 20085:21 pmRNSAnnual Report and Accounts
13th Jun 20089:17 amRNSDirectorate Change
4th Jun 20087:00 amRNSPreliminary Results
6th May 20087:02 amRNSMolectra - First Shipment
22nd Apr 200812:32 pmRNSHolding(s) in Company
15th Apr 20087:01 amRNSMolectra shareholding
10th Mar 20087:00 amRNSContract Win
8th Jan 20087:00 amRNSChange of Adviser
27th Sep 20077:01 amRNSInterim Results
25th Sep 200710:59 amRNSNotification of Interest
16th Aug 20071:04 pmRNSAIM Rule 26 Information
2nd Aug 20077:00 amRNSMolectra Loan Agreement
2nd Aug 20077:00 amRNSEnvironmental Award
14th Jun 20072:10 pmRNSResult of AGM
11th Jun 20074:34 pmRNSRe: Annual Report & Accounts
11th Jun 20077:00 amRNSResignation of Chairman
1st May 20077:03 amRNSFinal Results
26th Mar 20077:03 amRNSMolectra Report & Investment
23rd Mar 20075:05 pmRNSHolding in Company
23rd Mar 20075:05 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.